Why Prosecuting Covid Fraudsters Misses the Real Scam

Why Prosecuting Covid Fraudsters Misses the Real Scam

Locking up a single bad actor over a $66 million Covid test billing scheme feels like justice. It isn't. It's theater.

When a headline breaks about an Indian-origin entrepreneur or any other operator getting indicted in the US for billing insurers or public programs tens of millions for phantom or questionable Covid-19 tests, the standard reaction is predictable. Outrage. Finger-pointing. Calls for stiffer sentences and louder press conferences from the Department of Justice.

That reaction is lazy. Worse, it lets the actual architecture of the crime off the hook.

I have spent years watching health-care billing disputes, payer audits, and compliance overhauls play out from inside the trenches. I have seen companies blow millions trying to patch holes with more paperwork after the money already walked out the door. Every time a headline like this hits, the industry acts shocked that someone gamed a system designed to pay first and ask questions later—if it asks at all.

The real story isn't that one schemer tried to extract $66 million from a pandemic-era billing apparatus. The real story is that the payment rails made extracting $66 million frictionless.


The Lazy Consensus About Health-Care Fraud

Read the typical coverage of a massive diagnostic billing indictment and you will see the same three assumptions repeated like gospel:

  1. Fraud happens because individuals lack moral restraint. Catch the greedy operator, put them in handcuffs, and the system heals.
  2. Oversight failed because the pandemic created an emergency. Once emergency rules expire, normal controls supposedly restore order.
  3. Higher billed totals equal higher economic loss. If claims hit $66 million, taxpayers or insurers lost $66 million in clean cash.

Every one of those assumptions falls apart under scrutiny.

Moral restraint is not a control mechanism. In any high-margin, high-volume billing environment, bad actors will test the boundaries. If a system rewards volume with minimal pre-payment verification and slow post-payment clawbacks, opportunists don't even have to be sophisticated. They just have to submit claims faster than auditors can review them.

Emergency authorities accelerated the trend, sure. Waiving prior authorizations, expanding reimbursement pathways, and pushing rapid diagnostic access during a public health crisis removed friction for legitimate clinics and labs. That part is well-documented. Yet anyone who understands revenue cycle management and claims adjudication knows that "pay and chase" existed long before 2020 and has outlived emergency declarations across multiple areas of health care.

And billed dollars are not paid cash. In health care billing, charged amounts, allowed amounts, adjudicated payouts, and eventual recoveries or forfeitures are completely different numbers. Headlines routinely treat a headline dollar figure—whether tied to submitted claims, alleged schemes, or statutory calculations—as a simple pile of bills paid in full. Conflating those numbers obscures how money actually moves through payer networks, third-party administrators, and government programs.


Defining the Terms Before We Talk Blame

People throw around words like fraud, waste, and abuse as if they are synonyms. They aren't. Mixing them up is how executives and commentators miss where the real vulnerability lives.

  • Fraud involves intentional deception or misrepresentation made knowing it could result in an unauthorized benefit—such as billing for tests never performed, fabricating medical necessity, or using stolen patient identifiers.
  • Waste involves careless or inefficient spending without necessarily proving deceptive intent—such as ordering redundant panels or failing to track inventory properly.
  • Abuse sits in the gray zone—practices inconsistent with sound fiscal, business, or medical standards that drive up costs without crossing the exact evidentiary line of criminal fraud.

Proving criminal fraud requires proving intent beyond a reasonable doubt. That bar is high for a reason. Prosecutors have to show that a defendant didn't just run a sloppy operation, misunderstand a billing code, or get burned by a billing vendor; they have to show willful deception.

When a case lands in federal court, the indictment focuses on the defendant's conduct, shell structures, false claims, or kickback and billing mechanics. That makes sense in a courtroom. A criminal trial is about individual guilt under statutes like the False Claims Act or health-care fraud provisions.

As an analysis of how the market failed, though, focusing almost exclusively on the indicted individual is like blaming a pickpocket for a subway turnstile left wide open all day.


The Wrong Question Everyone Is Asking

Look at how people search and talk about stories like a $66 million Covid test scheme. They ask: How did this person pull off a $66 million scam? or Why wasn't this stopped sooner?

Those are the wrong questions.

The right question is: Why did our reimbursement architecture allow a single entity to generate tens of millions in billable volume before basic anomaly detection triggered a hard stop?

Think about how modern commerce works outside health care. If an online merchant suddenly tries to push tens of millions of dollars in unusual transactions through a payment processor, risk engines flag velocity spikes, mismatched fulfillment data, chargeback ratios, and identity anomalies in real time. Funds get held. Accounts get frozen.

Now contrast that with parts of health-care claims processing. Claims often move through clearinghouses, payers, and benefit managers across fragmented data silos. A lab or testing entity can submit high volumes of diagnostic claims using patient demographics pulled or purchased from questionable sources, pair them with standing or loosely verified orders, and collect reimbursements before clinical reality is ever checked against the invoice.

Consider a thought experiment. Imagine a scenario where a billing operation submits thousands of diagnostic claims tied to individuals who never asked for a test, never visited a collection site, and never received results. If the payer's system checks only basic formatting, active eligibility, and clean code combinations at intake, the claim passes. Even when red flags pop up later—like dozens of unrelated patients sharing an address, impossible daily test volumes at a single site, or rapid spikes in claims from a newly formed entity—clawing back already-disbursed funds through civil litigation, restitution orders, or asset forfeiture takes years. By the time prosecutors seize assets or win judgments, much of the money has already been spent, moved, or layered.

The incentive structure is upside down. The upside is immediate cash flow. The downside is delayed legal exposure years down the road.


Addressing the Questions People Actually Ask

"How do people get away with billing millions for fake or questionable tests?"

They exploit speed, fragmentation, and distance between the person billed and the payer.

Patients rarely scrutinize every explanation of benefits for routine or pandemic-era testing, especially when told testing was free or covered. Payers process massive claim volumes under tight statutory or contractual turnaround rules. Clearinghouses route transactions without acting as substantive medical reviewers. When you combine high reimbursement rates per unit with high volume and weak pre-payment verification, the math scales fast—even if a percentage of claims gets rejected or audited later.

"Why didn't regulators or insurers catch it earlier?"

Because post-payment analytics are slower than automated claim submission.

Data analytics teams at insurers and government oversight bodies—including the HHS Office of Inspector General and the Department of Justice—do catch outliers. Patterns like sudden billing spikes, unusual provider-patient geography, or high denial-to-submission shifts show up in data. The catch is timing. Turning statistical anomalies into a vetted referral, a subpoena trail, and a criminal indictment takes months or years. Fraudsters operate on a weekly cash cycle; law enforcement operates on a legal evidence cycle.

"Does prosecuting high-profile cases deter future schemes?"

Only a little, and mostly at the margins.

High-profile indictments send a clear signal that federal authorities are watching health-care billing and won't let pandemic-era excuses shield blatant schemes forever. In the health-care compliance world, heavy hitters like the HHS Office of Inspector General, the Department of Justice's Health Care Fraud Unit, and major payer special investigation units have built serious analytical muscle around outlier detection.

Still, deterrence has a ceiling when the structural temptation remains high. A new operator simply changes the corporate name, tweaks the billing arrangement, hires a different third-party biller, and tries to stay under the radar just long enough to get paid. You cannot deter your way out of broken incentives without fixing the payment plumbing.


Where My Contrarian View Has Blind Spots

Let's be honest about the downside of pushing a system-design critique this hard.

First, if you slam the brakes too hard on pre-payment edits and automated claim approvals, you punish legitimate providers. Smaller clinics, rural labs, and honest operators already drown in prior authorizations, arbitrary downcoding, and delayed payments. If every outlier triggers an automatic freeze, legitimate care and legitimate testing get bogged down in administrative purgatory.

Second, reducing a criminal case to "broken systems" can sound like excusing deliberate theft. It isn't. Someone who knowingly submits false claims for tests never performed made a choice. Accountability matters. Without criminal prosecution and civil recovery, there is no consequence for willful fraud.

Third, real-world fraud schemes are often messy. Sometimes a business starts with a real service, scales recklessly, cuts corners on documentation or consent, partners with shady marketers, and crosses the line into outright fraud along the way. Drawing a neat line between sloppy compliance and criminal intent is rarely simple on the ground.

Ignoring those trade-offs makes a contrarian take sound glib. Acknowledging them makes it real.


What Actually Works Instead of Performative Outrage

If you run a payer, a health plan, a self-funded employer benefit program, or a compliance team, waiting for the next DOJ press release is not a strategy. Here is what actually moves the needle:

  1. Audit velocity and concentration, not just unit codes. A clean billing code means nothing if one entity bills an improbable volume of tests in a single zip code or ties dozens of claims to recycled contact details. Flag anomalous growth curves before payouts clear.
  2. Require lightweight proof of real-world encounter. You don't need a 40-page dossier for every diagnostic test, but you do need verifiable linkage between the patient, the order, and the specimen collection or home-kit fulfillment. No verifiable encounter, no automatic payout.
  3. Separate marketing leads from clinical orders. High-pressure outreach, lead generators, and third-party marketers are classic flashpoints in diagnostic billing disputes. Treat any claim originating through aggressive external lead generation with heightened scrutiny.
  4. Stop treating clawbacks as a win. Recovering a fraction of a scheme years later after legal fees and asset dissipation is damage control, not prevention. Shift resources earlier in the lifecycle—right where money leaves the account.

Stop Worshiping the Arrest

A $66 million Covid test fraud charge makes a great headline. It gives the public a villain, gives commentators a talking point, and gives the system a brief moment to look tough.

Fix the payment incentives that made the $66 million possible in the first place, or you'll just be reading the exact same headline with a different name next year.

JE

Jun Edwards

Jun Edwards is a meticulous researcher and eloquent writer, recognized for delivering accurate, insightful content that keeps readers coming back.